Lack of minocycline efficiency in genetic models of Huntington's disease.

Abstract excerpt

According to the recent controversy regarding the effects of minocycline in the R6/2 transgenic model of Huntington's disease (HD), this tetracycline has been re-evaluated in another model, the N171-82Q strain. Ten miligrams per kilogram minocycline was given daily from the age of 2 mo, corresponding to an early symptomatic stage. We did not observe improvement in survival, weight loss, or motor function in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anti-Bacterial Agents
• Share to Caspase 1
• Share to Huntingtin Protein